You're signed outSign in or to get full access.
Octagon Capital Advisors LP
Octagon Capital Advisors LP is an SEC-registered investment management firm headquartered in New York, NY. Incorporated in Delaware, the firm was founded in 2019 and operates as a hedge fund focused on managing institutional client assets in public equity markets, primarily within healthcare and biotechnology sectors. As of 2024, it manages over $450 million in AUM and employs a modest team to serve its clients.
Investment Strategy
Octagon Capital Advisors LP primarily utilizes a fundamental, research-driven approach focused on investment opportunities in the life sciences, biotechnology, and healthcare sectors. The firm's strategy involves deep scientific diligence, thematic investing, and active portfolio management, seeking to identify undervalued public companies with significant growth potential in therapeutics, diagnostics, and medical technologies.
Latest 13F Filing Activity
Octagon Capital Advisors LP filed their most recent 13F report on Jun 30, 2025 disclosing 28 equity positions with a total 13F market value of $456M. The fund increased holdings in Verona Pharma PLC, Ars Pharmaceuticals Inc., Taysha Gene Therapies Inc. among other positions. Octagon Capital Advisors LP reduced exposure to Nuvation Bio Inc., Apellis Pharmaceuticals Inc., Taysha Gene Therapies Inc. among others.
Top Holdings
Equity Positions (28)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
D DNTH | DIANTHUS THERAPEUTICS INC | 9.57% | $43.6M | 2,341,667 | $23.31 | $18.63 | +$1.1M |
A AVBP | ARRIVENT BIOPHARMA INC | 9.30% | $42.4M | 1,946,054 | $19.08 | $21.77 | +$4.3M |
V VRNA | VERONA PHARMA PLC | 7.00% | $31.9M | 337,000 | $44.94 | $94.58 | +$18.1M |
T TSHA | TAYSHA GENE THERAPIES INC | 6.38% | $29.1M | 12,592,500 | $2.14 | $2.31 | +$14.2M |
S SPRY | ARS PHARMACEUTICALS INC | 5.17% | $23.6M | 1,350,000 | $15.20 | $17.45 | +$15.7M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more